Status:
UNKNOWN
Artificial Intelligence-assisted Evaluation of Pigmented Skin Lesions
Lead Sponsor:
Assuta Hospital Systems
Conditions:
Melanoma
Pigmented Skin Lesion
Eligibility:
All Genders
18-90 years
Brief Summary
Malignant melanoma (MM) is a deadly cancer, claiming globally about 160000 new cases per year and 48000 deaths at a 1:28 lifetime incidence (2016). The golden standard, dermoscopy, enables Dermatolog...
Detailed Description
Background Malignant melanoma (MM) is a deadly cancer, claiming globally about 160000 new cases per year and 48000 deaths \[1\]. The incidence rate for MM ascended between 1950 and 2007 more than 17-...
Eligibility Criteria
Inclusion
- Patient aged 18-90 years
- A pigmented lesion by dermoscopy.
- Clinical management by the examining dermatologist results in biopsy
- The diameter of the pigmented area is between 1 and 40 millimeters
- The patient has consented to participate in the study and has signed the Informed Consent Form
Exclusion
- Non intact skin (ulcers, bleeding)
- The lesion is located within 1 cm of the eye
- The lesion is located on mucosal surfaces
- The lesion is on or under nails
Key Trial Info
Start Date :
December 6 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2019
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03362138
Start Date
December 6 2017
End Date
March 31 2019
Last Update
September 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maccabi Healthcare Clinic
Tel Aviv, Israel, 59485